With each passing day, The University of Texas MD Anderson Cancer Center moves steps closer to ending cancer once and for all. With your generous support, the progress being made today holds promise for a cancer-free tomorrow. We thank you for your interest in the Moon Shots Program™ and for your commitment to the milestones we will reach together.

The Moon Shots Program is a boundary-pushing research initiative that focuses on fostering innovation and collaboration in the prevention, early detection and treatment of 13 disease sites. The shared goal to end cancer is what binds each Moon Shot™ initiative together and unites multidisciplinary teams at MD Anderson. The most groundbreaking aspect of the Moon Shots Program is the unprecedented level of collaborative work and resources that go into MD Anderson’s world-renowned research and patient care. Ending cancer is a collective endeavor that involves the effort of many: patients, staff, clinicians, researchers and, most importantly, the generosity of our committed supporters.

We respectfully ask that you consider a gift of $<GIFT AMOUNT> to provide the foundation for a scientific revolution in cancer research. Making Cancer History® is a team effort that includes the generosity of people, like you, who stand with MD Anderson in our mission to advance cancer care and research. If you have questions or would like more information, please contact me at <PHONE> or <EMAIL>. Thank you for your compassionate consideration of this request.

Sincerely,

<NAME>
<INITIALS>
Case for Support or Exec Summary

“We will use this money to pay for gas and lodging. We live six hours from Houston and come frequently for procedures, treatments and consultations. Thank you so much for this great help. We appreciate it with all our heart.”

MD Anderson Patient

Patient Assistance Funds

Help for Cancer Patients in Need

Summary

At The University of Texas MD Anderson Cancer Center, patient assistance programs administered through the Department of Social Work are philanthropic vehicles established primarily by caring individuals, foundations and other organizations. They help qualified, financially disadvantaged patients pay for non-medical expenses associated with their cancer care. These expenses, such as transportation and lodging, can cause financial distress for patients undergoing outpatient treatment or follow-up for extended periods, often weeks at a time.

To support patient assistance, a donor may contribute to an existing fund or create a new fund in one of two ways: by making a one-time, "spendable" gift or by establishing an endowment that provides annual support in perpetuity. These funds are the mainstay of this social work service, and they provide an excellent avenue for those who want to aid patients in need. However, patient assistance funds may not be designated to benefit any specific individual.

Who is eligible for patient assistance funds?

Generally, these funds serve any qualified adult or pediatric patient whose eligibility is determined by the donor and MD Anderson’s Department of Social Work. Funds donated by the Cure Sonia Foundation would be directed toward patients who have been diagnosed with leukemia. Typically, patients assisted by these funds range from indigent Texas residents to members of the working middle class from any geographic area who are uninsured or under insured. The latter patients are caught in the gap between indigence and financial dependence due to unreimbursed expenses incurred as a result of their disease. They and/or their families struggle to meet travel and lodging expenses while also maintaining households, but earn too much to qualify for public assistance or other programs.

There is a name and a face behind every cancer diagnosis. The patients we serve come from various walks of life and socio-economic situations; no two are alike. The financial needs, however, are similar in that they are immense. Cancer is one of the most expensive diseases to treat and costs continue to rise. The average patient will find that their financial resources are exhausted quite early in their treatment process. One of our patients said, “All this is still new and we are struggling financially. The assistance has been much needed and very helpful.”
Thank you for your generous gift of $<AMOUNT> to support The University of Texas MD Anderson Cancer Center’s Moon Shots Program®, our most comprehensive program to date that accelerates the application of knowledge and scientific breakthroughs to save lives. Achievements are made and promises are realized every day due to your confidence in MD Anderson’s mission to end cancer.

From the latest breakthroughs in immunotherapy to discoveries from the nation’s largest clinical trial program, the Moon Shots® initiative is revolutionizing every facet of cancer care. We have made significant achievements in areas of research and clinical care, but much more can and must be done. Thanks to your generosity, we will continue to make tidal waves of change in prevention, early detection and treatment of cancer. For as long as we have been at the forefront of care and major advancements in cancer research, our philanthropic partners have remained committed and vital to our mission.

Thank you for your support of the Moon Shots Program and for joining us in Making Cancer History®.

Sincerely,

Peter WT Pisters, M.D.
President

PWP.ish
Michael H. Kroll M.D.

Dr. Kroll, Professor of Medicine and Chief of Benign Hematology at The University of Texas MD Anderson Cancer Center, is a hematologist and oncologist with clinical research specialties in hemostasis and thrombosis. Since 2008, he has been providing benign hematology service to patients at MD Anderson.

After earning his undergraduate degree in biology from the State University of New York Binghamton, Dr. Kroll received his medical degree in medicine from Cornell University. He completed his residency in internal medicine at Brown University and then continued to pursue a subspecialty fellowship in hematology/oncology at the Harvard Medical School.

Dr. Kroll’s postdoctoral career focused extensively on the mechanisms of platelet-dependent thrombosis. His team was among the first groups to determine that the von Willebrand factor binding to platelet glycoprotein Iib activates platelets. During his time at MD Anderson, Dr. Kroll began clinical research in the prevention and treatment of venous thromboembolism (VTE) in cancer patients, focusing on those diagnosed with ovarian cancer, breast cancer, gynecologic malignancies, and acute leukemia. His assessments of VTE risk factor in acute leukemia patients led him to develop a scoring system that would predict longevity among patients receiving inferior vena caval (IVC) filters and determine the most appropriate type of IVC filter to be utilized.
Providing Support for the Development Office

- Quick Tips
- Priority Program Spotlight
- Proofread/edit

Priority Program Spotlight
August 2018

What?
Liver Cancer is particularly devastating in Texas, where its death rates are two to three times the liver cancer death rates of the US. This recently reinvigorated Priority Program focuses on developing early-detection and prevention programs for liver cancer.
Request for Writers' Services

Date Request Submitted: 5/29/2018

Donor Information
Name: [Redacted]
Title: [Redacted]
Address: [Redacted]
Phone Number: 925-287-4201
Donor Website:

Field Office/Requestor: Nett Susan S
Assistant: Smith Monica A

Proposed Program/Project: [Redacted]
Gift Amount/Range: [Redacted]

Required Forms and Attachments

Guidelines/Application Forms Attached (if Foundation)?
☐ Yes
☐ None Required

Relevant Background Information Attached?
☐ Yes
☐ None Required/Available

Materials Required

Number of copies needed:
☐ Letter of Inquiry
☐ Proposal
☐ Cover Letter for Proposal
☐ Proposal in Letter Form
☐ Executive Summary
☐ Blurp/Paragraph
☐ Edit Only
☐ Other: Complete attached online form

Signed by: Dr. Peter Pisters
Salutation:
Organization Information

General Information
- Name of applicant organization: The University of Texas MD Anderson Cancer Center
- Address: 1515 Holcombe Blvd., Unit 705
- City: Houston
- State: TX
- Zip Code: 77030
- Phone: (713) 503-9982, (713) 503-4115
- Fax Number: (713) 503-4115
- Web Address: 1515 Holcombe Blvd.
- Tax ID: 746001118

Attach a copy of your 501(c)(3) tax determination letter
Choose File: No file chosen
Upload

Background Information
- Mission Statement:
  The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.
July 23, 2018

Dear [Name],

On behalf of everyone at The University of Texas MD Anderson Cancer Center, I would like to thank you and [Company] for your dedicated support and continued commitment. Your unwavering generosity over the past 16 years has been vital to our mission of advancing cancer research, enhancing patient care and, ultimately, ending this dreaded disease. We are immensely grateful for the faith you have in our ability to achieve this mission.

At MD Anderson, we work tirelessly to offer hope to cancer patients and their families. The Moon Shots Program™ remains the cornerstone of our efforts to dramatically reduce the incidence and mortality of cancer. Within six years, the scope of this research initiative has expanded from a dedicated focus on eight disease types to 13. Through the generosity of our charitable partners, the Moon Shots Program has fostered innovation and collaboration in the early detection, prevention and treatment of several cancer areas.

The enclosed grant report highlights how your support has catalyzed the progress made by the Acute Myeloid Leukemia and Myelodysplastic Syndrome (AML/MDS) Moon Shot™ team this past year. A [gift] from [Company] has enabled the AML-MDS Moon Shot team to perform experiments that characterize the molecular mechanisms of MDS, a disease that originates in bone marrow cells, and to identify potential therapeutic targets.

Since establishing hypomethylating agents (HMA) as the current standard of care in MDS, MD Anderson has been a leader in conducting research and developing treatments for the disease. Funding from [Company] has supported genetic sequencing experiments whose outcomes ensure that MD Anderson remains on the frontlines of MDS research. Data from these experiments have identified a biological distinction between CMP- and GMP-pattern MDS, thus indicating that these two patterns will most likely benefit from two different avenues of immunotherapy.

With the foundation’s backing, researchers also have been able to test the efficacy of the drug venetoclax, both alone and in combination with HMA, in MDS models. These findings ultimately verify venetoclax’s effectiveness in removing leukemia cells from the bone marrow of patients with CMP-pattern MDS. From here, researchers have been able to launch a Phase I clinical trial to test venetoclax in patients with MDS and validate the effects of targeting genes involved in inflammation as potential therapeutic targets. Further clinical development has the potential to aid patients in overcoming resistance to drugs, expand research on the CMP- and GMP-pattern MDS and develop strategies that prevent relapse and minimize residual disease.

Based on our continuing progress, we fully expect that our outstanding team of researchers and physician-scientists will fulfill our overall goal of enhancing patient outcomes and survival rates for patients with AML and MDS. We truly appreciate [Company] for providing us with the opportunity to accelerate our basic, translational and clinical research and to provide our patients with these promising therapies.

We are on the horizon of a cancer-free future. As we continue to make critical advances in our laboratories, clinical trials and hospital rooms, we respectfully ask you to consider an additional gift in the amount of [Amount]. With your support, MD Anderson will remain on the forefront of scientific progress and innovation as a global leader in cancer research and care.

Funding from [Company] not only translates to cutting-edge technology, passionate personnel and clinical trial infrastructure that can advance cancer research; it also will translate to life-changing and lifesaving programs and treatments for our patients. Your generosity will help define the future of cancer medicine and the effects it has on patients across the globe.

Enclosed you will find the grant report and the Request for Grant Consideration Form. If you have any questions or would like more information, please contact Susan Nart at 713-563-9982 or via email at snart@mdanderson.org. Again, we deeply appreciate your past support, and we thank you for your thoughtful consideration of this important new request.

Sincerely,

[Signature]
Peter W.T. Pisters, M.D.
President

PWTP.Inh
The “Dictionary”

Thank You

• It is with profound appreciation
• I extend my most sincere gratitude
• I extend my most sincere appreciation
• With profound gratitude and a full heart I offer my thanks
• We are so grateful to you for
• Please extend my appreciation
• I want to express my gratitude
• Please accept my sincere thanks
• I offer my most heartfelt thanks
• Many thanks to
• You have my heartfelt thanks
• Please allow me to take this opportunity to offer a special thanks to you for
• I wish to express my heartfelt gratitude to you for
• With profound gratitude I offer my thanks
• On behalf of The University of Texas MD Anderson Cancer Center, thank you for
• Please accept my appreciation for

Moon Shots Program

These are various forms to describe what Moon Shots is, the impact we want to leave on our patients and our ultimate mission statement

• The Moon Shots Program is a boundary-pushing research initiative that focuses on fostering innovation and collaboration in the prevention, early detection and treatment of 13 disease sites.
• ...pioneering projects focused on prevention, early detection and treatment.
• The Moon Shots Program is a multidisciplinary, institution-wide think tank to tackle the issue and develop innovative approaches across prevention and policy, screening and early detection, and treatment development
• unprecedented in approach, comprehensiveness and lifesaving promise
• escalated efforts to share information, integrate resources and harness teamwork
• The goal is to dramatically reduce the incidence and mortality of cancer, so that the disease in all its forms is preventable, detectable, treatable and forgettable.
• The moon shots address a number of different diseases, but they share a single goal: end cancer.
• The Moon Shots Program aims to radically reduce the incidence and mortality of thirteen cancers now and all cancers in the future.
• a goal-oriented effort to implement large-scale projects and infrastructure designed to dramatically reduce cancer mortality within five to 10 years.
• the most ambitious and comprehensive effort ever launched by an academic institution
• harnesses large multidisciplinary teams, activates platforms in policy, education and drug development with industry-like execution, and promotes a culture of accountability and urgency.
• a new organizational paradigm—one which already has led to practice-changing progress against several cancers, including melanoma, chronic lymphocytic leukemia and ovarian cancer.
• raised more than $300 million in philanthropy to date and last year ranked No. 1 in IP-related revenue in the nation
Boot Walk to End Cancer

Creating profiles that encapsulate the artistic process behind every Boot Award and the stories that drive each artist.